Necrosis, sarcolemmal damage and apoptotic events in myofibers rejected by CD8+ lymphocytes: Observations in nonhuman primates

Neuromuscular Disorders

Volumn 22, Issue 11, 2012, Pages 997-1005

  Skuk, Daniel ^a   Tremblay, Jacques P ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Acute rejection; Apoptosis; CD8+ lymphocytes; Cell transplantation; Myofibers; Necrosis; Nonhuman primates

Indexed keywords

CASPASE 3; DYSTROPHIN; SPECTRIN; TACROLIMUS;

ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CD8+ T LYMPHOCYTE; CELL TRANSPLANTATION; GRAFT REJECTION; HISTOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTIC INFILTRATION; MACACA; MALE; MUSCLE BIOPSY; MUSCLE INJURY; MUSCLE NECROSIS; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; SARCOLEMMA;

ANIMALS; APOPTOSIS; CASPASE 3; CD8-POSITIVE T-LYMPHOCYTES; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MACACA; MUSCLE, SKELETAL; NECROSIS; SARCOLEMMA; TACROLIMUS;

EID: 84868145184     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2012.05.005     Document Type: Article

References (40)

1. Skuk D., Roy B., Goulet M., et al. Dystrophin expression in myofibers of Duchenne muscular dystrophy patients following intramuscular injections of normal myogenic cells. Mol Ther 2004, 9:475-482.
2. Skuk D., Goulet M., Roy B., et al. Dystrophin expression in muscles of Duchenne muscular dystrophy patients after high-density injections of normal myogenic cells. J Neuropathol Exp Neurol 2006, 65:371-386.
3. Skuk D., Goulet M., Roy B., et al. First test of a "high-density injection" protocol for myogenic cell transplantation throughout large volumes of muscles in a Duchenne muscular dystrophy patient: eighteen months follow-up. Neuromuscul Disord 2007, 17:38-46.
4. Skuk D. Myoblast transplantation for inherited myopathies: a clinical approach. Expert Opin Biol Ther 2004, 4:1871-1885.
5. Guerette B., Asselin I., Vilquin J.T., Roy R., Tremblay J.P. Lymphocyte infiltration following allo- and xenomyoblast transplantation in mdx mice. Muscle Nerve 1995, 18:39-51.
6. Irintchev A., Zweyer M., Wernig A. Cellular and molecular reactions in mouse muscles after myoblast implantation. J Neurocytol 1995, 24:319-331.
7. Wernig A., Irintchev A. "Bystander" damage of host muscle caused by implantation of MHC- compatible myogenic cells. J Neurol Sci 1995, 130:190-196.
8. Skuk D., Goulet M., Paradis M., Tremblay J.P. Myoblast transplantation: techniques in nonhuman primates as a bridge to clinical trials. Methods in bioengineering: cell transplantation 2011, 219-236. Artech House, Boston. A. Soto-Gutierrez, N. Navarro-Alvarez, I.J. Fox (Eds.).
9. Skuk D., Tremblay J.P. Intramuscular cell transplantation as a potential treatment of myopathies: clinical and preclinical relevant data. Expert Opin Biol Ther 2011, 11:359-374.
10. Rose S.M., Blustein N., Rotrosen D. Recommendations of the expert panel on ethical issues in clinical trials of transplant tolerance. National Institute of Allergy and Infectious Diseases of the National Institutes of Health. Transplantation 1998, 66:1123-1125.
11. Kirk A.D. Transplantation tolerance: a look at the nonhuman primate literature in the light of modern tolerance theories. Crit Rev Immunol 1999, 19:349-388.
12. Kirk A.D. Crossing the bridge: large animal models in translational transplantation research. Immunol Rev 2003, 196:176-196.
13. Levinson G., Hughes A.L., Letvin N.L. Sequence and diversity of rhesus monkey T-cell receptor beta chain genes. Immunogenetics 1992, 35:75-88.
14. Slierendregt B.L., van Noort J.T., Bakas R.M., Otting N., Jonker M., Bontrop R.E. Evolutionary stability of transspecies major histocompatibility complex class II DRB lineages in humans and rhesus monkeys. Hum Immunol 1992, 35:29-39.
15. Geluk A., Elferink D.G., Slierendregt B.L., et al. Evolutionary conservation of major histocompatibility complex-DR/peptide/T cell interactions in primates. J Exp Med 1993, 177:979-987.
16. Jaeger E.E., Bontrop R.E., Lanchbury J.S. Structure, diversity, and evolution of the T-cell receptor VB gene repertoire in primates. Immunogenetics 1994, 40:184-191.
17. Skuk D. Acute rejection of myofibers in nonhuman primates: Key histopathologic features. J Neuropathol Exp Neurol 2012, 71:398-412.
18. Berke G. The CTL's kiss of death. Cell 1995, 81:9-12.
19. Graubert T.A., Ley T.J. How do lymphocytes kill tumor cells?. Clin Cancer Res 1996, 2:785-789.
20. Shresta S., Pham C.T., Thomas D.A., Graubert T.A., Ley T.J. How do cytotoxic lymphocytes kill their targets?. Curr Opin Immunol 1998, 10:581-587.
21. Ham R.G., St. Clair J.A., Webster C., Blau H.M. Improved media for normal human muscle satellite cells: serum-free clonal growth and enhanced growth with low serum. In Vitro Cell Dev Biol 1988, 24:833-844.
22. Skuk D., Goulet M., Tremblay J.P. Use of repeating dispensers to increase the efficiency of the intramuscular myogenic cell injection procedure. Cell Transplant 2006, 15:659-663.
23. Engel A.G., Biesecker G. Complement activation in muscle fiber necrosis: demonstration of the membrane attack complex of complement in necrotic fibers. Ann Neurol 1982, 12:289-296.
24. Cullen M.J., Mastaglia F.L. Pathological reactions of skeletal muscle. Skeletal muscle pathology 1982, 88-139. Churchill Livingstone, London. F.L. Mastaglia, J. Walton (Eds.).
25. Hohlfeld R., Engel A.G., Goebels N., Behrens L. Cellular immune mechanisms in inflammatory myopathies. Curr Opin Rheumatol 1997, 9:520-526.
26. Arahata K., Engel A.G. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984, 16:193-208.
27. Engel A.G., Arahata K. Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol 1986, 17:704-721.
28. Arahata K., Engel A.G. Monoclonal antibody analysis of mononuclear cells in myopathies. IV: Cell-mediated cytotoxicity and muscle fiber necrosis. Ann Neurol 1988, 23:168-173.
29. Dalakas M.C. Muscle biopsy findings in inflammatory myopathies. Rheum Dis Clin North Am 2002, 28:779-798.
30. Engel A.G., Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984, 16:209-215.
31. Arahata K., Engel A.G. Monoclonal antibody analysis of mononuclear cells in myopathies. III: Immunoelectron microscopy aspects of cell-mediated muscle fiber injury. Ann Neurol 1986, 19:112-125.
32. Stadelmann C., Lassmann H. Detection of apoptosis in tissue sections. Cell Tissue Res 2000, 301:19-31.
33. Samali A., Zhivotovsky B., Jones D., Nagata S., Orrenius S. Apoptosis: cell death defined by caspase activation. Cell Death Differ 1999, 6:495-496.
34. Tews D.S. Muscle-fiber apoptosis in neuromuscular diseases. Muscle Nerve 2005, 32:443-458.
35. Dalakas M.C. Pathophysiology of inflammatory and autoimmune myopathies. Presse Med 2011, 40:e237-e247.
36. Dalakas M.C. Review: an update on inflammatory and autoimmune myopathies. Neuropathol Appl Neurobiol 2011, 37:226-242.
37. Schneider C., Gold R., Dalakas M.C., et al. MHC class I-mediated cytotoxicity does not induce apoptosis in muscle fibers nor in inflammatory T cells: studies in patients with polymyositis, dermatomyositis, and inclusion body myositis. J Neuropathol Exp Neurol 1996, 55:1205-1209.
38. Behrens L., Bender A., Johnson M.A., Hohlfeld R. Cytotoxic mechanisms in inflammatory myopathies. Co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells. Brain 1997, 120(Pt 6):929-938.
39. Eckle V.S., Buchmann A., Bursch W., Schulte-Hermann R., Schwarz M. Immunohistochemical detection of activated caspases in apoptotic hepatocytes in rat liver. Toxicol Pathol 2004, 32:9-15.
40. Tidball J.G., Albrecht D.E., Lokensgard B.E., Spencer M.J. Apoptosis precedes necrosis of dystrophin-deficient muscle. J Cell Sci 1995, 108(Pt 6):2197-2204.